Tesamorelin is a prescription injectable peptide sold in the United States as EGRIFTA SV. It is a lab made copy of growth hormone releasing hormone. The FDA approved it to reduce excess deep abdominal fat in adults living with HIV who have lipodystrophy. Its own label says it is not a weight loss drug.
What this peptide is, and who it is prescribed for
The approved product is made by Theratechnologies and given as an injection under the skin, once a day. Lipodystrophy means body fat sits in unusual places. In people living with HIV, that can mean a thick layer of fat deep inside the abdomen, packed around the organs. Clinicians call that layer visceral adipose tissue. It is harder to shift than the softer fat you can pinch, and it behaves differently in the body.
Two very different products share this active ingredient, and confusing them is the single biggest mistake readers make. One is the brand, which the FDA reviewed for safety, effectiveness and manufacturing quality before it went on sale. The other is compounded tesamorelin, mixed by a pharmacy and marketed by wellness and longevity clinics as a peptide for body composition. Compounded preparations are not FDA approved and are not reviewed for safety, effectiveness or quality before sale, even though the branded version of the same molecule was. Nothing about the brand’s approval carries over to a compounded vial.
Approved Brand vs. Compounded Tesamorelin
| EGRIFTA SV (Approved Brand) | Compounded Preparation | |
|---|---|---|
| FDA review before sale | Yes, safety, effectiveness, quality | No, not FDA approved |
| Approved use | HIV-associated lipodystrophy | None; off-label by definition |
| Manufacturing standard | FDA-inspected commercial facility | Varies by pharmacy |
| Strength & purity | Fixed, batch-tested | Depends on pharmacy |
| Insurance | Submittable (prior auth required) | Rarely reimbursed |
Prescribing outside the approved group is legal in the United States, and doctors do it across many drug classes. That does not make the evidence equal. The published research sits overwhelmingly in adults with HIV associated abdominal fat accumulation, and a plain-language summary of the approved use is available in the patient overview from a major US clinic; see Mayo Clinic drug information for this hormone. If you are comparing injectables for general fat loss, start with the molecules that are actually approved for it in our Plain English Medication Library.
How it works inside the body
Growth hormone releasing hormone is a natural signal. It travels from the hypothalamus to the pituitary gland, a pea sized gland at the base of the brain, and tells it to release growth hormone in pulses. This peptide mimics that signal. Instead of injecting growth hormone directly, it prompts your own pituitary to make more of it, which keeps the release pattern closer to the body’s normal rhythm.
Growth hormone then acts on the liver, which produces insulin like growth factor 1, usually shortened to IGF-1. Higher growth hormone activity encourages the breakdown of stored fat. In studies, that effect showed up most in deep abdominal fat rather than in fat under the skin. A useful background summary of the mechanism appears in a peer reviewed research overview of this GHRH analogue: published review of the growth hormone releasing hormone analogue.
Two things follow from that mechanism, and both matter to patients. First, the drug depends on a working pituitary. If the hypothalamic pituitary axis has been disrupted, the signal has nothing to act on. Second, the label describes the effect on body weight as neutral. People in trials generally did not get lighter on the scale. Deep fat measured by CT scan changed, while total weight largely did not. A neutral clinical description of what the injection does is set out in a hospital patient guide to this injection.
Waist size is the rough proxy clinicians reach for when they want to gauge abdominal fat between scans. Putting your own tape measure reading into a ratio makes it easier to track.
Waist-to-height ratio
A single-number check that works across builds better than BMI, with one easy rule: keep your waist under half your height.
Measure at the navel, not at your belt line. Under 0.5 is the widely used cut-off for adults.
What the FDA label covers, and what it deliberately does not
The approved indication is narrow: reducing excess abdominal fat in HIV infected adult patients with lipodystrophy. The label then adds a set of limitations of use, which are worth reading as plainly as they are written.
- Long term cardiovascular safety has not been established.
- It is not indicated for weight loss management, because the effect on weight is neutral.
- There is no evidence it improves how well people stick to their HIV medicines.
- If deep abdominal fat has not gone down, the label tells prescribers to weigh the risks and benefits of continuing.
That last point answers the timeline question better than any before and after photo. In the pivotal research, deep belly fat was measured by scan after roughly six months of treatment, with longer extension periods. Response was not universal. Some people saw a meaningful drop in visceral fat, others did not, which is exactly why the label builds in a stop and reassess step. Anyone promising a fixed number of inches in a fixed number of weeks is going beyond the evidence.
Also worth saying: the effect is not a cure. Published follow up work indicates deep fat tends to return after the drug is stopped, because the underlying drivers have not changed. Diet, alcohol, activity, sleep and the rest of your medication list all keep doing their work in the background.
Side effects people report during treatment
Most reactions reported in trials were uncomfortable rather than dangerous, and they clustered in a few groups. The most frequently reported problems involved joints, muscles and the injection site.
- Joint pain, muscle pain, muscle spasm and pain in an arm or leg.
- Injection site reactions: redness, itching, bruising, swelling, rash or a lump under the skin.
- Fluid retention, which can look like puffy ankles, swollen hands or a feeling of stiffness.
- Tingling, numbness or reduced sensation, sometimes in the hands.
- Nausea, vomiting, stomach upset and general rash.
- Rises in blood sugar, which matter more if you already have prediabetes or diabetes.
People often search for side effects broken out by sex. The trials enrolled both men and women, and the labeling does not describe two separate side effect profiles. The important sex specific point is different: pregnancy is a contraindication, so anyone who could become pregnant needs that conversation before the first injection. A patient level list of what to report is kept up to date by the National Library of Medicine in its consumer drug information page for this injection.
Because growth hormone activity affects fluid and glucose handling, the side effects you feel first are often the ones that fade or settle. The ones that need monitoring, such as blood sugar and IGF-1, do not announce themselves. That is the argument for a program that runs labs rather than one that simply ships vials.
Warnings, who should avoid it, and interaction risk
The safety section of the label is where the seriousness lives, and it is short enough to read in full. Four themes drive it.
Cancer risk. Because the drug raises a growth factor, any pre-existing cancer should be inactive and its treatment finished before starting. If there is any sign of a cancer returning, treatment is stopped. This is a hard boundary, not a caution.
Rising IGF-1. The label instructs prescribers to monitor IGF-1 during treatment, because the long term effects of keeping that growth factor elevated are unknown. Persistent elevations are a reason to consider stopping.
Fluid retention. Swelling, joint pain and carpal tunnel type symptoms in the wrist can all come from held fluid.
Blood sugar and allergy. Glucose intolerance and new or worsening diabetes are recognised risks, so glucose is followed. Hypersensitivity reactions, including rash, hives, flushing and breathing trouble, are also described.
The label lists people who should not use it at all: those whose hypothalamic pituitary axis has been disrupted by pituitary surgery, a pituitary tumour, head irradiation or head trauma; people with active cancer; anyone with a known allergy to the drug or to mannitol; and pregnant patients. Full contraindication and monitoring text sits in the official prescribing information hosted on the National Library of Medicine label database.
Interactions are less about a long blocklist and more about mechanism. Changes in growth hormone activity can change how the liver processes certain drugs, so medicines with a narrow safety margin deserve extra attention. Tell the prescriber about every antiretroviral, insulin or other diabetes medicine, steroid, thyroid medicine, anticonvulsant and supplement you take. Do not assume a telehealth intake form will catch a drug it never asked about.
Compounded peptide versus the approved brand
Most people searching for this molecule online are not being offered the brand. They are being offered a compounded vial from a wellness clinic or a peptide focused telehealth program. The two are not interchangeable, and the table below is the short version of why.
| Point of difference | EGRIFTA SV (approved brand) | Compounded preparation |
|---|---|---|
| FDA review before sale | Yes, for safety, effectiveness and quality | No, compounded drugs are not FDA approved |
| Approved use | Excess abdominal fat in adults with HIV and lipodystrophy | None; use is off label by definition |
| Manufacturing standard | Commercial manufacturing under FDA inspection | Varies by pharmacy; 503A pharmacies serve individual prescriptions, 503B outsourcing facilities register with the FDA |
| Strength and purity | Fixed and tested per batch | Depends on the pharmacy’s testing and sourcing |
| Insurance | Can be submitted, usually with prior authorization | Rarely reimbursed |
Two regulatory details are worth knowing before you hand over a card. First, the FDA distinguishes traditional 503A pharmacies from 503B outsourcing facilities, which register with the agency and are subject to inspection; the agency publishes its current list of registered outsourcing facilities. Second, compounding from a bulk substance depends on where that substance sits in the agency’s review process, which is tracked on the FDA page covering bulk substances nominated for use in compounding. General background on what compounding can and cannot claim is in the agency’s compounding questions and answers.
Anything sold as research use only, sold without a prescription, or shipped from overseas sits outside all of this. Pharmacy and telehealth certification status can be checked independently through a third party healthcare certification service. Comparing how programs disclose their pharmacy partner is also a fair test of the rest of the operation, and the Telehealth Provider Directory is a reasonable place to see how openly they do it.
Cost without insurance, and what moves the monthly number
Self-pay pricing for this molecule is not one number. It splits sharply between the branded injection, which is a specialty product routed through specialty pharmacies, and compounded vials sold through subscription style clinics. Among self-pay programs the directory tracks for this peptide, the lowest recurring monthly figure is a month. Advertised prices move, so treat any figure as a snapshot rather than a fixture.
What actually moves the monthly total:
- Brand versus compounded. This is the largest single factor by a wide margin.
- The pharmacy. Different compounders price the same molecule differently, and sourcing and testing costs sit inside that number.
- Vial size and how long a vial lasts you. A cheaper vial that runs out sooner is not cheaper.
- Program fees. Some monthly prices bundle the consult, follow ups and shipping. Others bill them separately.
- Labs. IGF-1 and glucose monitoring may be included, billed as an add on, or left to you and your own lab.
- Intro versus renewal pricing. A first month discount tells you nothing about month six.
Insurance is a separate track, and it works on the plan or membership fee basis rather than on copays, which vary by plan and state. No page can promise coverage. What can be said plainly is that the branded product is a specialty drug with a narrow indication, so plans typically require prior authorization and documentation tied to HIV associated lipodystrophy, and denials are common. Compounded peptides are usually a cash purchase. Ask your plan directly, in writing, and ask which pharmacy it wants the prescription sent to. Broader context on how specialty drug costs land on patients is tracked in independent health cost policy research from KFF. People living with HIV should also ask their care team about state assistance programs, which have their own rules.
If you are weighing a year on any injectable, the yearly figure is the honest one to look at rather than the monthly headline.
What a year actually costs
Programmes quote a monthly headline. Add the medication, the labs and the renewal price and the real number is usually different.
Advertised prices change often and intro pricing rarely lasts. Ask what the renewal rate is before you commit to a plan.
For how monthly totals are laid out across programs, the Sample Savings Report shows the format, and the ratings approach behind provider pages is set out in our Provider Scoring Methodology.
How it compares with sermorelin, ipamorelin and GLP-1 medicines
These names get bundled together in marketing, which helps nobody. Here is the honest separation.
Versus sermorelin. Sermorelin is also a growth hormone releasing hormone analogue, so the mechanism is related. The difference is regulatory and structural: the branded sermorelin product is no longer marketed in the United States, so what patients encounter is almost always compounded. Direct head to head evidence for body composition is limited.
Versus ipamorelin. Ipamorelin works through a different pathway, mimicking ghrelin at the growth hormone secretagogue receptor. It has no FDA approved product, so every use is compounded and off label. Clinics sometimes pair the two peptides. That combination has not been reviewed or approved as a treatment, and combining substances does not combine their evidence.
Versus semaglutide and other GLP-1 drugs. This is the comparison people most often get wrong. GLP-1 medicines act on appetite and gut signalling and are approved, in specific products, for type 2 diabetes or chronic weight management. Tesamorelin is weight neutral by its own label and targets a specific deep fat depot in a specific population. They are not substitutes. If general weight management is the goal, the relevant reading is Semaglutide For Weight Management, the comparison in Tirzepatide Cost And Side Effects, and the program breakdown in Choosing A GLP-1 Telehealth Program.
Bodybuilding and anti aging searches deserve a straight answer too. There is no approved use of this peptide for muscle building, athletic performance or longevity, and it is banned in tested sport. Marketing that leans on before and after photos is showing you selected outcomes, not data.
Questions worth asking, and when to get urgent help
Bring a short list to the consult. These questions separate a careful program from a shipping operation.
Questions to Ask Before Starting
- Is this the FDA-approved brand or a compounded preparation, and which pharmacy fills it?
- What is the approved indication, am I inside it or outside it?
- Will you check IGF-1 and blood sugar before and during treatment, and who pays for labs?
- Do I have any past cancer or pituitary problem that rules this out?
- What is the plan if my deep abdominal fat does not change?
- What does the monthly price include, and what does it cost at renewal?
- Who do I contact if I get swelling, a rash, or worsening numbness?
- Is this the FDA approved brand or a compounded preparation, and which pharmacy fills it?
- What is the approved indication, and am I inside it or outside it?
- Will you check IGF-1 and blood sugar before starting and during treatment, and who pays for those labs?
- Do I have any history, including any past cancer or pituitary problem, that rules this out?
- What is the plan if my deep abdominal fat does not change?
- What does the monthly price include, and what does it cost at renewal?
- Who do I contact if I get swelling, a rash or worsening numbness?
Stop and get medical help quickly for signs of an allergic reaction: hives, swelling of the face, lips or throat, wheezing or trouble breathing. Also seek prompt care for a new lump or a change in a known lump, sudden severe headache or vision changes, rapid swelling in the legs or hands, chest pain, or signs of high blood sugar such as heavy thirst, frequent urination and blurred vision. Injection site changes that spread, blister or ooze deserve a same day call rather than a wait and see.
Ongoing coverage of how these programs operate sits in our Telehealth Reporting And Analysis, and the measurement tools referenced above live in the Free Health Calculators collection.
Authoritative sources
- Drugs@FDA approved product database
- CDC information on living with HIV
- FDA postmarket drug safety information
Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.
